AN INTRODUCTION TO fflSTAMINE
Histamine is largely contained in the fixed mast cells and the circulating basophils of the blood. By its action on smooth muscle it facilitates vasodilatation and permits the movement of phagocytic cells across the tissues to their point of action during the inflammatory response. While not the only important "chemical" effector of the inflammatory response, it is a major candidate for the initiation of its clinical manifestations. This was demonstrated very elegantly by Lorenz and his colleagues (1982) , who administered low doses of histamine (1-2 ng/ml plasma) to informed volunteers, reproducing the manifestations of minor anaphylactoid shock.
The release of histamine is facilitated by immune reaction (IgE or other antibodies), by complement activation, by the presence of immune complexes (or aggregates of molecules resembling such complexes) and directly by the action of drugs and other chemicals upon cell surface receptors.
It is possible to make some generalizations (Lorenz et al., 1982) about the concentration of plasma histamine and the observed clinical manifestations (table I) . At concentrations greater than 30 ng/ml plasma, life-threatening situations are almost certainly present. Generally, the release of even 1-2 ng ml" 1 is sufficient to generate mild clinical manifestations, but at this concentration wide individual tolerances to histamine become apparent. Further, it seems apparent that, while about 30% of the population as a whole are capable of releasing such small quantities of histamine (1-2 ng ml" 1 ) in response to a wide range of substances administered i.v., such release may be self-limiting and not indicative of a tendency to release harmful amounts of histamine in that individual upon further stimulus. In their extensive review of histamine and its clinical significance, Lorenz and his colleagues (1981) suggest that immediate histamine release reactions fall into two broadly defined groups: anaphylactoid reactions and allergoid reactions. Anaphylactoid reactions (Watkins and Clarke, 1978) are likely to involve varying degrees of systemic histamine action such as hypotension, tachycardia or cardiac arrhythmia, and bronchospasm, as well as the usual cutaneous effects such as flushing and urticaria; allergoid reactions predominantly exhibit only cutaneous effects (Lorenz et al., 1980) . Cutaneous manifestations being the most prevalent, it is obvious that minor anaphylactoid reactions will be clinically undistinguishable from allergoid reactions; the latter at worst have nuisance value and are largely self-limiting, but the former disguises several mechanisms and implications for the patient's future care.
Medical decision making
In terms of untoward response, atracurium resembles tubocurarine in producing a high incidence of essentially cutaneous manifestations. Tubocurarine continues to be quite extensively used in anaesthesia since, in clinical practice, it has proved no more hazardous than many other drugs in current use. The inference is that most adverse reactions to both tubocurarine and atracurium are self-limiting, generally harmless, allergoid responses. However, it would be very unwise to attempt to use clinical manifestations alone to provide a diagnosis of anaphylactoid or allergoid reaction.
Bronchospasm may occur for a variety of reasons unconnected with drug therapy. Tachycardia may be induced by surgery, or manipulation, or by various drug effects (e.g. of atropine) unconnected with the release of histamine. Laboratory analysis thus becomes essential in defining reactions, particularly the measurement of plasma histamine release (Lorenz et al., 1981) .
HISTAMINE RELEASE BY ATRACURIUM
All i.v. substances are capable of releasing histamine by a variety of mechanisms, although with different drugs broad patterns of preferred mechanisms occur (Watkins, 1981) . Following multiple exposure of any patient to any drug the possibility of immune sensitization and Type I hypersensitivity response increases. So far no genuine immune reaction to atracurium appears to have been reported.
While our own studies (Westminster Hospital Study: Barnes, De Renzy-Martin, Thomas and Watkins, in preparation) indicated plasma histamine release (< 2 ng/ml plasma) to atracurium in a number of patients, in the absence of clinical response, this release was of an order similar to that encountered with thiopentone alone and did not generally correlate with a high incidence (> 50% of study group) of skin flushing or mild degrees of hypotension. In the few patients (table II) in whom more significant clinical manifestations were encountered it was considered that the histamine waves released by both thiopentone and atracurium had become superimposed, prolonging the action of the released histamine and generating a composite anaphylactoid response implicating both drugs.
The cutaneous response to atracurium appears predominantly the result of skin histamine release, but the mechanism remains unknown. Such response has a similarity to that produced on occasion by etomidate or dextrans, and even to the "needle response" (Watkins, 1981) .
The most hazardous systemic response to atracurium is a version of aggregate anaphylaxis. The latter may be initiated by the formation of aggregates of mixed, precipitated drugs, with or without inclusion of certain of the patient's plasma proteins. Sufficient precipitate is often produced when the anaesthetist fails to wash out an indwelling cannula between the administration of different drugs. It is most marked with thiopentone and atracurium. The usual manifestation is simply a reddening along the site of the injection vein, representing the precipitation of various types of complexes (compare thiopentone injections alone), but if the precipitate is of the appropriate size and concentration it will initiate acute, often life-threatening bronchospasm when swept into the capillaries of the lungs. Figure 1 records a typical case report to this laboratory. The absence of hypotension in such cases is most striking and the circulating aggregates can be measured. The combination fentanyl-etomidateatracurium seems free of this complication, but nevertheless saline washings should be used between all drugs.
None of this explains the high level of cutaneous manifestations observed with atracurium. As remarked upon earlier, these apparently allergoid reactions are similar in appearance and frequency to those initiated by tubocurarine administration, yet the general level of plasma histamine release by atracurium is on par with that of pancuronium, while that of tubocurarine is some four times higher (Moss et al.,1982) . We must look elsewhere for explanations and indications of clinical significance. Robertson and colleagues (1983) studied the responses in volunteers to intradermal injections of diluted atracurium, tubocurarine and vecuronium. As expected, a high incidence of weal and flare reactions was observed to the two former drugs, but not to vecuronium. On this basis these workers proposed that vecuronium was likely to be the safer drug when used clinically. This is not a valid conclusion for any drug tested in this way: even drugs like pethidine and atropine, with a low incidence of anaphylactoid reactions when administered i.v., produce weal and flare reactions when injected intradermally. In order to investigate the true prognostic value of intradermal testing with atracurium and tubocurarine, the Sheffield Unit skin-tested 22 female patients who gave informed consent 24 h before undergoing gynaecological surgery for non-malignant conditions (Wood et al., 1985) . A high incidence of positive "intradermal" weals was obtained at dilutions of 1:1000 of the clinical dosage with each drug, and half the test group responded positively to both drugs (table III) . The test conditions and criteria of a positive reaction (a weal of 1 cm in diameter or greater, persisting for more than 30 min) were those described by Fisher (1984) . Irrespective of the findings, 24 h later the patients had anaesthesia induced with thiopentone and were then given atracurium or tubocurarine on a randomized schedule. There were no clinically significant anaphylactoid reactions and such flushing and transient minor hypotension which was observed was surprisingly biased towards the non-reactors in table III.
SKIN RESPONSES TO NEUROMUSCULAR BLOCKERS
In retrospective surveys of clinically severe anaphylactoid reactions throughout the U.K. and reported to the Sheffield-based National Adverse Anaesthetic Reaction Advisory Service (NAARAS), a ranking table of neuromuscular blocking agents co-administered with the hypnotic agents (table IV) did appear to support the observations of Robertson and colleagues (1983) . It can be seen that tubocurarine and atracurium share an intermediate position in the ranking, behind suxamethonium and alcuronium, but considerably ahead of pancuronium and vecuronium. This ranking is not in the expected use of these drugs, with the exception of the extensive use of suxamethonium. However, although specific IgE antibodies were detected against suxamethonium in one patient, the hypnotic drugs appeared to be implicated in most reactions. The ranking is thus likely to represent the relative risks of various drug combinations, rather than specific individual neuromuscular agent responses. Current studies in this Department (Watkins, Wild and Clarke, 1985) and with our colleagues in Belfast (Lavery, Clarke and Watkins, 1985) indicate that the release of histamine by both tubocurarine and atracurium occurs in intradermal tests predominantly in patients with low circulating concentrations of plasma IgE (10 u. ml" 1 ). About 20 % of the population possess such low concentrations, and these also appear to predispose to clinical systemic anaphylactoid response by nonimmune histamine release.
CONCLUSIONS
In clinical terms, atracurium emerges as a safe drug with useful neuromuscular blocking properties. It does have a tendency to produce a high incidence of cutaneous manifestations, the majority of which are harmless allergoid reactions resulting in skin histamine, rather than plasma histamine release. A number of systemic anaphylactoid situations may also be generated which reflect both the chemical nature of the drug and insufficient care by the anaesthetist. While for the most part these additional reactions are also harmless clinically, the mixing and precipitation which occurs between thiopentone and atracurium injected through the same indwelling cannula without saline wash-through may initiate systemic aggregate anaphy laxis and potentially life threatening bronchospasm.
